Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-20T11:27:11.508Z Has data issue: false hasContentIssue false
  • English
  • Français

Delayed onset of action of antidepressant drugs? Survey of recent results

Published online by Cambridge University Press:  16 April 2020

H.H. Stassen ,
J Angst  and
A Delini-Stula
H.H. Stassen
Affiliation:
Psychiatric University Hospital Zurich, Research Department, PO Box 68, CH-8029Zurich, Switzerland
J Angst
Affiliation:
Psychiatric University Hospital Zurich, Research Department, PO Box 68, CH-8029Zurich, Switzerland
A Delini-Stula*
Affiliation:
Psychiatric University Hospital Zurich, Research Department, PO Box 68, CH-8029Zurich, Switzerland
*
*Present address: Roche International Clinical Research Center, F-67380 Lingolsheim, France.
Get access

Summary

The onset of action of antidepressant drugs was investigated on the basis of two independent multicenter, double-blind efficacy studies comparing amitriptyline (n = 120), oxaprotiline (n = 120), imipramine (n = 506) and moclobemide (n = 580) with placebo (n = 189 + 191). The samples consisted of in- and outpatients diagnosed, according to Diagnostic and Statistical Manual (DSM)-III criteria, as suffering from major depressive disorder. Measures of efficacy criteria were the Hamilton Rating Scale for Depression (HAM-D), the Hamilton Rating Scale for Anxiety (HAM-A) and the Zung Self-Rating Depression scale. By using the Sustained Relative Improvement (SRI) criterion, onset of action was determined in each individual patient as that time point in the 30 day observation period at which a 20% baseline score reduction was achieved without subsequent deterioration. Analogously, a response to treatment was defined as a 50% baseline score reduction. As expected, highly significant differences between active drugs and placebo were found with respect to the total number of improvers and responders. Significant differences between treatment modalities surfaced in the percentage rate as well as the time distribution of premature withdrawals. Yet, unexpectedly, among improvers, the time spans to onset of improvement were found to be independent of treatment modality as indicated by virtually identical cumulative percentages of improvers throughout the whole observation period. The picture was essentially the same for the HAM-A and Zung assessments, except for a significant time lag between observer- and self-ratings. In particular, our analyses revealed no evidence for a delayed onset of action under various antidepressants with large biochemical and pharmacological differences in comparison to placebo. Moreover, the early onset of improvement was highly predictive of later outcome: on average, 70% of the patients showing improvement within the first 14 days became responders. Applying survival-analytical methods, we found that differences between active treatments and placebo emerged within the first 5 days and reached a point of maximum distinction around day 14. After this time point, differences between treatment modalities remained constant until the end of the observation period. According to our data, 20–25% of the patients were, on average, ‘true’ drug responders, thus suggesting that the therapeutic qualities of antidepressants do not lie in the suppression of symptoms, but rather are related to their ability to elicit and maintain certain conditions which allow recovery in a subgroup of patients who would otherwise remain non-responders.

Keywords

onset of actionantidepressantsplaceboresponse to treatment
Type
Research Article
Information
European Psychiatry , Volume 12 , Issue 4 , 1997 , pp. 166 - 176
Copyright
Copyright © Elsevier, Paris 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

†

Reproduced with permission of Georg Thieme verlag, Stuttgart

References

Angst, JTime-lag of antidepressant effectIn: Symposia Medica Hoechst 13, Symposium Rome 1977: Depressive Disorders 1978 Schattauer Stuttgart468Google Scholar
Angst, JDelini-Stula, AStassen, H.H.Is a cutoff score a suitable measure for treatment outcome? A methodological metaanalysis Hum Psychopharmacol 8 1993 311–317CrossRefGoogle Scholar
Angst, JStassen, H.H.Methodische Aspekte von Studien zur antidepressiven WirksamkeitIn: Steinberg, RPhilipp, MMöller, HJSpezielle Aspekte der antidepressiven Therapie 1994 MMV Medizin Verlag Munich147–166Google Scholar
Blier, Pde Montigny, CChaput, YA role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence J Clin Psychiatry 51 1990 14–20Google ScholarPubMed
DaPrada, MKettler, RKeller, H.H.Haefely, WENeurochemical effects in vitro and in vivo of the antidepressant RO 11-1163, a specific and short-acting MAO-A inhibitor Mod Prob Pharmacopsychiatry 19 1983 231–245CrossRefGoogle Scholar
Donlon, PTBiertuemphel, HWillenbring, MAmoxapine and amitriptyline in the outpatient treatment of endogenous depression J Clin Psychiatry 42 1981 11–15Google ScholarPubMed
Delini-Stula, AHauser, KBaumann, Pet al. Stereospecificity of behavior and biochemical responses to oxaprotiline — a new antidepressant Adv Biochem Psychopharmacol 31 1982 265–275Google ScholarPubMed
Gachoud, JPMikkelsen, HAmmar, SWidlöcher, DJouvent, RTheoretical consideration and perspectives on the onset of action of moclobemide Psychopharmacology 106 1992 96–97CrossRefGoogle Scholar
Greenhouse, JBKupfer, DJFrank, EJarrett, DBRejman, KAAnalysis of time to stabilization in the treatment of depression: biological and clinical correlates J Affective Disord 13 1987 259–266CrossRefGoogle ScholarPubMed
Greenhouse, JBStangl, DBromberg, JAn introduction to survival analysis: statistical methods for analysis of clinical trial data J Consult Clin Psychol 57 1989 536–544CrossRefGoogle ScholarPubMed
Grey, PFluoxetine and onset of its therapeutic effect Am J Psychiatry 150 1993 984Google ScholarPubMed
Hekimian, LJFiredhoff, AJDeever, EA comparison of the onset of action and therapeutic efficacy of amoxapine and amitriptyline J Clin Psychiatry 39 1978 633–637Google ScholarPubMed
Katz, MMKoslow, SHMaas, JWet al. The timing, specificity and clinical prediction of tricycling drug effects in depression Psychol Med 17 1987 297–309CrossRefGoogle Scholar
Khan, ACohen, SDager, SAvery, DHDunner, DLOnset of response in relation to outcome in depressed outpatients with placebo and imipramine J Affective Disord 17 1989 33–38CrossRefGoogle ScholarPubMed
Kuny, SStassen, H.H.Speaking behavior and voice sound characteristics in depressive patients during recovery J Psychiat Res 27 1993 289–307CrossRefGoogle ScholarPubMed
Mason, BJKocsis, JHFrances, AJMann, JJAmoxapine versus amitriptyline for continuation therapy of depression J Clin Psychopharmacol 10 1990 338–343CrossRefGoogle ScholarPubMed
Meya, UFichte, KAntidepressiver Wirkungseintritt von Rolipram, einem Antidepressivum mit einem neuen Wirkmechanismus, im Vergleich zu Imipramin Nervenarzt 62 1991 288–291Google Scholar
Quitkin, FMRabkin, JGMarkowitz, JMet al. Use of pattern analysis to identify true drug response Arch Gen Psychiatry 44 1987 259–264CrossRefGoogle ScholarPubMed
Quitkin, FMMcGrath, PJRabkin, JGet al. Different types of placebo response in patients receiving antidepressants Am J Psychiatry 148 1991 197–203Google ScholarPubMed
Quitkin, FMRabkin, JGStewart, JWet al. Heterogeneity of clinical response during placebo treatment Am J Psychiatry 148 1991 193–196Google ScholarPubMed
Quitkin, FMStewart, JWMcGrath, PJet al. Further evidence that a placebo response to antidepressants can be identified Am J Psychiatry 150 1993 566–570Google ScholarPubMed
Roffmann, MGould, EFBrewer, SJet al. A double blind comparative study of oxaprotiline with amitriptyline and placebo in moderate depression Curr Ther Res 32 1982 247–256Google Scholar
Stassen, H.H.Delini-Stula, AAngst, JTime course of improvement under antidepressant treatment: a survival-analytical approach Eur Neuropsychopharmacol 3 1993 127–135CrossRefGoogle ScholarPubMed
Stassen, H.H.Angst, JDelini-Stula, ASeverity at baseline and onset of improvement in depression. Meta-analysis of imipramine and moclobemide versus placebo Eur Psychiatry 9 1994 129–136CrossRefGoogle Scholar
Wachtel, HDysbalance of neuronal second messager function in the actiology of affective disorders: a pathophysiological concept hypothesising defects beyond first messenger receptors J Neurol Transm 75 1989 21–29CrossRefGoogle Scholar
Waldmeier, PCBaumann, PAHauser, KMaître, LStorni, AOxaprotiline, a nonadrenaline uptake inhibitor with an active and inactive enantiomer Biochem Pharmacol 31 1982 2169–2176CrossRefGoogle Scholar
Willner, PSensitization to the actions of antidepressant drugsEmmett-Oglesby, MWGoudie, AJ eds. Psychoactive Drugs tolerance and sensitization 1989 Humana Press Clifton407–459Google Scholar
Submit a response

Comments

No Comments have been published for this article.